Yakup Ergün, Medical Oncologist at Bower Hospital, shared on X:
“First-line ivonescimab+taxane in advanced TNBC (n=36): ORR 80%, mPFS 15.2 mo. In CPS<10 disease, ORR was 79.3% and mPFS 13 mo—the key signal. Promising, but a small single-arm phase 2. Its place in the ASCENT-03/04 and Dato-DXd era needs phase 3 validation.”
Title: First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial
Authors: Xiying Shao, Can Tian, Zhanhong Chen, Jian Huang, Yongsheng Wang, Tao Sun, Tienan Yi, Yifen Wu, Weihua Sun, Xufang Yu, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia, Xiaojia Wang, Quchang Ouyang
You can also explore: Oral SERDs in Breast Cancer: Powerful Shift From Rescue to Platform Therapy